InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) has been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $7.00.

Several research firms have commented on IFRX. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. Oppenheimer assumed coverage on InflaRx in a report on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Cantor Fitzgerald raised their target price on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $2.24 on Friday. The company has a market cap of $161.93 million, a P/E ratio of -3.15 and a beta of 2.44. InflaRx has a 1 year low of $0.74 and a 1 year high of $2.95. The firm has a 50-day simple moving average of $2.11 and a two-hundred day simple moving average of $1.39.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. As a group, equities research analysts expect that InflaRx will post -0.33 EPS for the current year.

Hedge Funds Weigh In On InflaRx

Several institutional investors have recently bought and sold shares of IFRX. ADAR1 Capital Management LLC acquired a new position in shares of InflaRx in the first quarter valued at approximately $142,000. XTX Topco Ltd acquired a new stake in shares of InflaRx in the fourth quarter valued at $135,000. Suvretta Capital Management LLC boosted its holdings in InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares during the period. Quadrature Capital Ltd acquired a new position in InflaRx during the 4th quarter worth $104,000. Finally, Eversept Partners LP grew its stake in InflaRx by 1.5% during the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after purchasing an additional 26,677 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.